查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1138273

全球癌症疫苗市场-2022-2029

Global Cancer Vaccines Market - 2022-2029
出版日期: | 出版商: DataM Intelligence | 英文 180 Pages | 商品交期: 约2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

市场动态

市场参与者对癌症疫苗的临床试验数量不断增加，预计将推动市场增长。

胰腺导管腺癌，称为 PDAC，是最常见的胰腺癌类型，尚无有效治疗方法。 mRNA 疫苗製造商 BioNTech 发布了针对 PDAC 的疫苗的 1 期临床试验数据。 Bio-NTech 开发的一种 mRNA 疫苗用于将新抗原遗传密码传递到患者的细胞中。新抗原是癌细胞製造的蛋白质，由细胞製造的代码指导。这种蛋白质的产生有助于触发免疫系统对肿瘤本身的攻击。此外，GSK plc 正在开发 BLENREP（belantamab mafodotin），这是一种针对成熟 B 细胞血清型的 ADC，用于治疗多发性骨髓瘤。目前处于III期临床试验阶段。

此外，根据牛津大学和路德维希癌症研究所的一项研究，牛津阿斯利康的 COVID-19 疫苗技术可能应用于癌症治疗。当在动物肿瘤模型中进行评估时，这种癌症疫苗接种增强了癌症免疫疗法的功效并增加了侵入肿瘤的抗肿瘤 T 细胞的水平。此外，免疫疗法和疫苗联合使用比单独免疫疗法显示出更大的肿瘤缩小效果，提高了小鼠的存活率。此外，codagenix 获得 FDA 批准其用于 CodaVax-RSV 的研究药物申请，这是一种减毒鼻 RSV 疫苗候选者。因此，从上述陈述来看，预计市场将在预测期内受到驱动。

限制

癌症疫苗研发成本高、单一疫苗生产时间长、监管审批慢等预计会在预测期内阻碍市场。我来了。

行业分析

癌症疫苗市场根据各种行业因素（包括波特五力、未满足的需求、定价分析、供应链分析和监管分析）对市场进行了深入分析。

COVID-19 影响分析

COVID-19 大流行对市场产生了适度的影响。随着 COVID-19 病例数量的增加，世界各地的医疗保健系统都将重点放在疾病控制上，推迟了包括癌症在内的其他慢性病的预防、检测和治疗。牛津大学和阿斯利康公司的研究人员正在使用相同的方法来製造治疗性癌症疫苗，并在动物研究中取得了可喜的结果。大流行之后，科学家和政□□府比以往任何时候都更加努力和更快地生产疫苗来控制病毒。因此，疫苗研究得到了发展。摆脱这场危机，信使 RNA 等技术将证明其治疗癌症等其他疾病的有效性和潜力。这一进展发生在研究人员研究利用免疫系统对抗肿瘤的其他尖端癌症治疗方法之际。

另一方面，大流行扰乱了癌症疫苗的供应炼和流程。因此，COVID-19 大流行正在影响市场。但是，预计这种情况将在预测期内逐渐改善。

全球癌症疫苗市场报告提供大约 45 多个市场数据表、40 多个数字和 180 页。

内容

第1章研究方法与范围

  • 调查方法
  • 调查目的和范围

第 2 章市场定义和概述

第 3 章执行摘要

第 4 章市场动态

  • 市场影响因素
    • 驱动程序
    • 市场进入者增加的癌症疫苗临床试验有望推动市场增长
  • 限制因素
    • 癌症疫苗开发的高成本预计将阻碍市场增长。
  • 机会
  • 影响分析

第5章行业分析

  • 供应链分析
  • 定价分析

第 6 章 COVID-19 分析

  • COVID-19 的市场分析
    • COVID-19 之前的市场情景
    • COVID-19 的当前市场情景
    • COVID-19 后或未来情景
  • COVID-19 期间的价格动态
  • 供需范围
  • 大流行期间与市场相关的政府举措
  • 製造商的战略举措
  • 总结

第 7 章按类型

  • 预防癌症疫苗
  • 治疗性癌症疫苗

第 8 章技术

  • 树突状细胞 (DC) 癌症疫苗
  • 重组癌症疫苗
  • 抗原/辅助癌症疫苗
  • 全细胞癌疫苗
  • 病毒载体和 DNA 癌症疫苗

第 9 章按癌症类型

  • 前列腺癌
  • 宫颈癌
  • 肺癌
  • 膀胱癌
  • 其他

第 10 章按地区划分

  • 北美
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 意大利
    • 西班牙
    • 其他欧洲
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美洲
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 澳大利亚
    • 其他亚太地区
  • 中东和非洲

第 11 章竞争格局

  • 主要发展和战略
  • 公司份额分析
  • 产品基准
  • 值得关注的重点公司列表

第 12 章公司简介

  • ose-免疫
    • 公司简介
    • 产品组合和描述
    • 主要亮点
    • 财务摘要
  • Merck & Co. Inc.
  • IO Biotech
  • Medigene AG
  • Northwest Biotherapeutics
  • GlaxoSmithKline
  • Dendreon Pharmaceuticals LLC.
  • Dynavax Technologies Corporation
  • Immunophotonics
  • Codagenix（*LIST NOT EXHAUSTIVE）

第13章 DataM

简介目录
Product Code: DMPH1513

Market Overview

Cancer vaccines market size was valued USD million in 2021 and is estimated to reach USD million by 2029, growing at a CAGR of 18% during the forecast period (2022-2029).

Cancer is a malignant tumor caused by uncontrollable cell development in the body. It can be treated with a variety of drugs and vaccinations. Vaccines are widely classified as either preventative or therapeutic. Preventive cancer vaccinations are used to prevent oncovirus-caused cancer and to protect against human papillomavirus (HPV), whereas therapeutic vaccines stimulate the individual adaptive immune systems by employing tumor antigens. Cancer vaccines are available in various forms, including antigen, dendritic cell, and anti-idiotype.There are several vaccines such as personalized cancer vaccines, anthrax vaccines, and other types of vaccines.

Market Dynamics

Increasing clinical trials for cancer vaccines by the market players is expected to drive market growth.

Pancreatic Ductal Adenocarcinoma, also known as PDAC, is a prevalent type of pancreatic cancer for which there are no effective treatments. BioNTech, a manufacturer of mRNA vaccines, released phase-1 clinical trial data for its vaccine against PDAC. The neoantigen genetic code is delivered to the patient's cells using the mRNA vaccination created by BioNTech. The neoantigens, proteins made by cancer cells, are instructed to be produced by the cells by the code. The production of these proteins aids in triggering the immune system's attack on the tumor itself. Moreover, BLENREP (belantamab mafodotin), an ADC targeting B-cell maturation antigen type used to treat multiple myeloma, is being developed by GSK plc. It is now in Phase III.

Additionally, the Oxford-AstraZeneca COVID-19 vaccine's technology also has the potential to treat cancer, according to research from the University of Oxford and the Ludwig Institute for Cancer Research. The cancer vaccination improved the effectiveness of cancer immunotherapy when evaluated in animal tumor models, where it increased the levels of anti-tumour T cells invading the tumors. The combination of immunotherapy and the vaccine demonstrated a larger tumor size decrease than immunotherapy alone, and the mice's survival improved. Furthermore, codagenix received FDA clearance for an investigational new drug application for Live-Attenuated, Intranasal RSV Vaccine Candidate CodaVax-RSV. Thus, from the above statements, the market is expected to drive in the forecast period.

Restraint:

The high cost of developing cancer vaccines, the longer time required for manufacturing a single vaccine and lengthy regulatory approvals are some factors the market is expected to get hampered in the forecast period.

Industry Analysis

The cancer vaccines market provides in-depth analysis of the market based on various industry factors such as porter five forces, unmet needs, pricing analysis, supply chain analysis, regulatory analysis etc.

COVID-19 Impact Analysis

The COVID-19 pandemic has moderately impacted the market. As the number of COVID-19 cases increased, healthcare systems worldwide focused on controlling the illness and delaying the prevention, detection, and treatment of other chronic illnesses, including cancer. Researchers at the University of Oxford and AstraZeneca Plc are attempting to create a therapeutic cancer vaccine using the same technique, with encouraging findings reported in animal experiments. After the pandemic, scientists and governments worked harder and faster than ever to produce vaccines to help contain the virus. As a result, vaccine research has evolved. Because of the crisis, technologies like messenger RNA have proven their efficacy and potential to treat other diseases like cancer. The advancements come as researchers examine other cutting-edge cancer treatments that use the immune system to fight tumors.

In contrast, the pandemic interrupts the cancer vaccine supply chain and process. Thus, the COVID-19 pandemic has affected the market. However, the situation is expected to improve gradually in the forecast period.

Segment Analysis

Recombinant Cancer Vaccines segment is expected to hold the largest market share in the cancer vaccine market.

The recombinant cancer vaccines segment is expected to dominate in 2021. Recombinant vaccines are created using recombinant DNA technology. This involves the expression of an antigen in mammalian cells, which triggers an immunological response and purifies the antigen from these cells. Various viruses have undergone genetic modification to express tumor-associated antigens (TAA) for intramuscular or subcutaneous injection. Broad cell tropism, strong immunogenicity, and pre-existing neutralizing immunity, exclusively in those patients who received the vaccinia virus, are only a few advantageous characteristics of poxviruses as vectors for cancer vaccines (the smallpox vaccine). Canarypox, fowlpox, and vaccines have all been studied therapeutically for cancer vaccination.

Additionally, a great deal of research is being done on viral recombinant cancer vaccines, primarily for cancer vaccination, which may have favorable outcomes in the future. Therefore, it has increased the demand for recombinant cancer vaccines. Thus, from the above statements, the market segment is expected to hold the largest market share in the forecast period.

Geographical Analysis

North American region holds the largest market share of the global cancer vaccines market.

In 2021, North America accounted for the highest revenue share. The increasing prevalence of cancer, rising research investments, increasing clinical trials by the market players and regulatory approvals for cancer vaccines are the factors the market is driven by in the forecast period. For instance, according to the American Cancer Society, in 2021, an estimated 1.9 million new cancer cases will be diagnosed, and there will be 608,570 cancer deaths in the United States. In contrast, in 2022, roughly 1.9 million people will be diagnosed with cancer in the United States. An estimated 287,850 women and 2,710 men will be diagnosed with breast cancer, which makes it the most common cancer diagnosis. Prostate cancer is the leading cancer diagnosis among men and the second most common overall, with 268,490 expected cases. Lung and bronchus cancer is the third most common cancer diagnosis, with an estimated 236,740 new cases.

Moreover, the 2020 American Society of Clinical Oncology (ASCO) Annual Meeting was held from May 29-31, 2020. Gilead Sciences, Inc. and Kite, a Gilead Company, announced that nine abstracts from their immuno-oncology research and development program, including three oral presentations, have been accepted. Abstracts at ASCO will showcase Kite's industry-leading cell therapy portfolio and magrolimab, an experimental anti-CD47 monoclonal antibody created by Forty-Seven, Inc., which Gilead just purchased. Thus, from the above statements, the North American region accounted for the largest market share in the forecast period.

Competitive Landscape

Major key players in the cancer vaccines market are ose-immuno, Merck & Co. Inc., IO Biotech, Medigene AG, Northwest Biotherapeutics, GlaxoSmithKline, Dendreon Pharmaceuticals LLC., Dynavax Technologies Corporation, Immunophotonics, Codagenix.

Northwest Biotherapeutics Inc.:

Overview:

Northwest Biotherapeutics Inc. is a biotechnology company involved in developing cancer vaccines. The target is a broad range of solid-tumor cancers. A customized vaccination is created by the corporation using a patented manufacturing method. The product portfolio includes product candidates such as DCVax-L for patients with brain cancer, DCVax-Direct for direct injection into all forms of solid tumor malignancies that are incurable, and DCVax for late-stage ovarian cancer. The U.S. Food and Drug Administration have given approval for DCVax-Prostate, which is used to treat late-stage prostate cancer.

Product Portfolio:

DCVAX TECHNOLOGY: DCVax is a platform technology for delivering dendritic cell based therapeutic vaccines for various cancers, including glioblastoma multiforme (GBM).

The global cancer vaccines market report would provide an access to an approx. 45+market data table, 40+figures and 180pages.

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

4. Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
    • 4.1.2. Increasing clinical trials for cancer vaccines by the market players is expected to drive market growth.
  • 4.2. Restraints:
    • 4.2.1. The high cost of developing cancer vaccines is expected to hamper the market growth.
  • 4.3. Opportunity
  • 4.4. Impact Analysis

5. Industry Analysis

  • 5.1. Supply Chain Analysis
  • 5.2. Pricing Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 7.1.2. Market Attractiveness Index, By Type Segment
  • 7.2. Preventive Cancer Vaccines*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 7.3. Therapeutic Cancer Vaccine

8. By Technology

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Technology
    • 8.1.2. Market Attractiveness Index, By Technology Segment
  • 8.2. Dendritic Cells (DC) Cancer Vaccines*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 8.3. Recombinant Cancer Vaccines
  • 8.4. Antigen/Adjuvant Cancer Vaccines
  • 8.5. Whole Cell Cancer Vaccines
  • 8.6. Viral Vector & DNA Cancer Vaccines

9. By Cancer Type

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Cancer Type
    • 9.1.2. Market Attractiveness Index, By Cancer Type Segment
  • 9.2. Prostate Cancer*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 9.3. Cervical Cancer
  • 9.4. Lung Cancer
  • 9.5. Bladder Cancer
  • 9.6. Others

10. By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 10.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Technology
    • 10.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Cancer Type
    • 10.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.2.6.1. U.S.
      • 10.2.6.2. Canada
      • 10.2.6.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 10.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Technology
    • 10.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Cancer Type
    • 10.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.3.6.1. Germany
      • 10.3.6.2. U.K.
      • 10.3.6.3. France
      • 10.3.6.4. Italy
      • 10.3.6.5. Spain
      • 10.3.6.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Technology
    • 10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Cancer Type
    • 10.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. Brazil
      • 10.4.6.2. Argentina
      • 10.4.6.3. Rest of South America
  • 10.5. Asia Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Technology
    • 10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Cancer Type
    • 10.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. China
      • 10.5.6.2. India
      • 10.5.6.3. Japan
      • 10.5.6.4. Australia
      • 10.5.6.5. Rest of Asia Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Technology
    • 10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Cancer Type

11. Competitive Landscape

  • 11.1. Key Developments and Strategies
  • 11.2. Company Share Analysis
  • 11.3. Product Benchmarking
  • 11.4. List of Key Companies to Watch

12. Company Profiles

  • 12.1. ose-immuno*
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Key Highlights
    • 12.1.4. Financial Overview
  • 12.2. Merck & Co. Inc.
  • 12.3. IO Biotech
  • 12.4. Medigene AG
  • 12.5. Northwest Biotherapeutics
  • 12.6. GlaxoSmithKline
  • 12.7. Dendreon Pharmaceuticals LLC.
  • 12.8. Dynavax Technologies Corporation
  • 12.9. Immunophotonics
  • 12.10. Codagenix(*LIST NOT EXHAUSTIVE)

13. DataM Intelligence

  • 13.1. Appendix
  • 13.2. About Us and Applications
  • 13.3. Contact Us